Drug intelligence / Profile preview

cyclophosphamide + doxorubicin + paclitaxel + sargramostim

Development stage: Preclinical
Lead developer: Partner Therapeutics
Modality: Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination chemotherapy regimen consisting of cyclophosphamide (an alkylating agent that damages DNA), doxorubicin (an intercalating agent that damages DNA), paclitaxel (a taxane that stabilizes microtubules), and sargramostim (a granulocyte-macrophage colony-stimulating factor). This combination likely represents a modified version of the AC-T regimen with sargramostim added to stimulate white blood cell production and reduce the risk of neutropenia.

Targets

TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)DNA

Beyond the preview

Go deeper on cyclophosphamide + doxorubicin + paclitaxel + sargramostim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + doxorubicin + paclitaxel + sargramostim.

Explore the full profile